Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ord Shs V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Post by BobTheKnob2on Apr 11, 2017 5:29pm
239 Views
Post# 26109401

Why is this so undervalued? See quote FYE 2016 financials

Why is this so undervalued? See quote FYE 2016 financials

Earlier today the year-end financials were released. Found this snippet in the middle without any fanfare.

Aveda ended the year with a net asset value per share(6) of $1.19, $15.1 million in working capital with a working capital ratio of 2.0:1, and undrawn cash availability of $35.5 million on its senior debt facility.
 

So why is this stock trading at half this value, even though it traded at around this level near the end of 2016. No wonder management is picking up shares hand over fist.

https://www.avedaenergy.com/investor-hub/press-releases/press-release-details/2017/Aveda-Transportation-and-Energy-Services-Announces-2016-Results-and-Provides-Operational-Update-for-the-First-Quarter-of-2017/default.aspx

Bullboard Posts